Skip to main content
SpringerLink
Log in

Treatment of B-Cell Lymphoma

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1192 Accesses

Abstract

Sjögren’s syndrome (SS) displays the highest incidence of malignant lymphoproliferative disorders among all of the autoimmune diseases. This association was highlighted in studies performed at the National Institutes of Health in the 1970s [1, 2] and verified in a meta-analysis that estimated the risk of Non-Hodgkin’s lymphoma (NHL) among the classic autoimmune diseases [3]. This meta-analysis reported that the possibility of an overt malignant lymphoproliferation is higher among SS patients (random effects standardized incidence rate (SIR) of 18.9 [95% confidence interval 9.4, 37.9]).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kassan SS, Thomas TL, Moutsopoulos HM, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888-92.

    PubMed  CAS  Google Scholar 

  2. Bunim JJ, Talal N. Development of malignant lymphoma in the course of Sjogren’s syndrome. Trans Assoc Am Physicians. 1963;76:45-56.

    Google Scholar 

  3. Zintzaras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337-44.

    Article  PubMed  Google Scholar 

  4. Suarez F, Lortholary O, Hermine O, et al. Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood. 2006;107:3034-44.

    Article  PubMed  CAS  Google Scholar 

  5. Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum. 1999;42:1765-72.

    Article  PubMed  CAS  Google Scholar 

  6. Baimpa E, Dahabreh IJ, Voulgarelis M, et al. Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. Medicine (Baltimore). 2009;88:284-93.

    Article  Google Scholar 

  7. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Mod Pathol. 2000;13:193-207.

    Article  PubMed  CAS  Google Scholar 

  8. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjogren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites and are not associated with viruses. Blood. 1997;90:766-75.

    PubMed  CAS  Google Scholar 

  9. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst. 2006;98:51-60.

    Article  PubMed  Google Scholar 

  10. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796-803.

    Article  PubMed  CAS  Google Scholar 

  11. Pelstring RJ, Essell JH, Kurtin PJ, Cohen AR, Banks PM. Diversity of organ site involvement among malignant lymphomas of mucosa-associated tissues. Am J Clin Pathol. 1991;96:738-45.

    PubMed  CAS  Google Scholar 

  12. Dogan A, Du M, Koulis A, et al. Expression of lymphocyte homing receptors and vascular addressins in low-grade gastric B-cell lymphomas of mucosa-associated lymphoid tissue. Am J Pathol. 1997;151:1361-9.

    PubMed  CAS  Google Scholar 

  13. Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren’s syndrome) begin as nonmalignant antigen-selected expansions. Blood. 1998;91:1864-72.

    PubMed  CAS  Google Scholar 

  14. Martin T, Weber JC, Levallois H, et al. Salivary gland lymphomas in patients with Sjogren’s syndrome may frequently develop from rheumatoid factors B cells. Arthritis Rheum. 2000;43:908-16.

    Article  PubMed  CAS  Google Scholar 

  15. D’Elios MM, Manghetti M, Almerigogna F, et al. Different cytokine profile and antigen-specificity repertoire in Helicobacter pylori-specific T cell clones from the antrum of chronic gastritis patients with or without peptic ulcer. Eur J Immunol. 1997;27:1751-5.

    Article  PubMed  Google Scholar 

  16. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology. 1987;11:445-62.

    Article  PubMed  CAS  Google Scholar 

  17. DiGiuseppe JA, Corio RL, Westa WH. Lymphoid infiltrates of the salivary glands: pathology, biology and clinical significance. Curr Opin Oncol. 1996;8:232-7.

    Article  PubMed  CAS  Google Scholar 

  18. Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within target tissue of an autoimmune disease. The salivary glands of patients with Sjogren’s syndrome. J Clin Invest. 1998;102:938-46.

    Article  PubMed  CAS  Google Scholar 

  19. Adamson TC, Fox RI, Frisman DM, et al. Immunohistologic analysis of lymphoid infiltrates in primary Sjogren’s syndrome using monoclonal antibodies. J Immunol. 1983;130:203-8.

    PubMed  Google Scholar 

  20. Boumba D, Skopouli FN, Moutsopoulos HM. Cytokine mRNA expression in the labial salivary gland tissues from patients with primary Sjogren’s syndrome. Br J Rheumatol. 1995;34:326-33.

    Article  PubMed  CAS  Google Scholar 

  21. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol. 1999;17:1254-8.

    PubMed  CAS  Google Scholar 

  22. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-95.

    Article  PubMed  CAS  Google Scholar 

  23. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802-6.

    PubMed  CAS  Google Scholar 

  24. Ambrosetti A, Zanotti R, Pattaro C, et al. Most cases of primary salivary mucosa-associated lymphoid tissue lymphoma are associated either with Sjoegren syndrome or hepatitis C virus infection. Br J Haematol. 2004;126:43-9.

    Article  PubMed  Google Scholar 

  25. Montalbán C, Castrillo JM, Abraira V, et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of the prognostic factors in 143 patients. Ann Oncol. 1995;6:355-62.

    PubMed  Google Scholar 

  26. Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol. 1997;15:1624-30.

    PubMed  CAS  Google Scholar 

  27. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628-38.

    PubMed  CAS  Google Scholar 

  28. Hammel P, Haioun C, Chaumette MT, et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol. 1995;13:2524-9.

    PubMed  CAS  Google Scholar 

  29. Conconi A, Martinelli G, Thiéblemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-5.

    Article  PubMed  CAS  Google Scholar 

  30. Jäger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20:3872-7.

    Article  PubMed  Google Scholar 

  31. Voulgarelis M, Petroutsos G, Moutsopoulos HM, et al. 2-chloro-2-deoxyadenosine in the treatment of Sjogren’s syndrome-associated B cell lymphoproliferation. Arthritis Rheum. 2002;46:2248-9.

    Article  PubMed  Google Scholar 

  32. Hussell T, Isaacson PG, Crabtree JE, et al. Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low-grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol. 1996;178:122-7.

    Article  PubMed  CAS  Google Scholar 

  33. Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64:958-60.

    Article  PubMed  CAS  Google Scholar 

  34. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740-50.

    Article  PubMed  CAS  Google Scholar 

  35. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66:351-7.

    Article  PubMed  CAS  Google Scholar 

  36. Quartuccio L, Fabris M, Moretti M, et al. Resistance to rituximab therapy and local BAFF overexpression in Sjögren’s syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma. Open Rheumatol J. 2008;2:38-43.

    Article  PubMed  CAS  Google Scholar 

  37. De Vita S, Dolcetti R, Ferraccioli G, et al. Local cytokine expression in the progression toward B cell malignancy in Sjögren’s syndrome. J Rheumatol. 1995;22:1674-80.

    PubMed  Google Scholar 

  38. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-26.

    PubMed  CAS  Google Scholar 

  39. Hainsworth JD, Litchy S, Burris HA 3rd, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261-7.

    Article  PubMed  CAS  Google Scholar 

  40. Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115:5210-7.

    Article  PubMed  CAS  Google Scholar 

  41. Orciuolo E, Buda G, Sordi E, et al. 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res. 2010;34:184-9.

    Article  PubMed  CAS  Google Scholar 

  42. Streubel B, Huber D, Wohrer S, et al. Frequency of chromosomal aberrations involving MALT1 in mucosa-associated lymphoid tissue lymphoma in patients with Sjogren’s syndrome. Clin Cancer Res. 2004;10:476-80.

    Article  PubMed  CAS  Google Scholar 

  43. Lévy M, Copie-Bergman C, Gameiro C, et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol. 2005;23:5061-6.

    Article  PubMed  Google Scholar 

  44. Liu H, Ruskon-Fourmestraux A, Lavergne-Slove A, et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet. 2001;357(9249):39-40.

    Article  PubMed  CAS  Google Scholar 

  45. Martinelli G, Laszlo D, Ferreri AJ, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979-83.

    Article  PubMed  CAS  Google Scholar 

  46. Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood. 2000;95:1950-6.

    PubMed  CAS  Google Scholar 

  47. Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1999;17:2486-92.

    PubMed  CAS  Google Scholar 

  48. Shin SS, Sheibani K. Monocytoid B-cell lymphoma. Am J Clin Pathol. 1993;99:421-5.

    PubMed  CAS  Google Scholar 

  49. Koh LP, Lim LC, Thng CH. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol. 2000;17:225-8.

    Article  PubMed  CAS  Google Scholar 

  50. Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford). 2004;43:1050-3.

    Article  CAS  Google Scholar 

  51. Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long-term remission of Sjögren’s syndrome-associated aggressive B-cell non-Hodgkin’s lymphomas following administration of combined B-cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65:1033-7.

    Article  PubMed  CAS  Google Scholar 

  52. Brown JR, Gaudet G, Friedberg JW, et al. Autologous bone marrow transplantation for marginal zone non-Hodgkin’s lymphoma. Leuk Lymphoma. 2004;45:315-20.

    Article  PubMed  Google Scholar 

  53. Rossi D, Gaidano G. Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. Hematology. 2002;7:239-52.

    Article  PubMed  CAS  Google Scholar 

  54. Neumeister P, Hoefler G, Beham-Schmid C, et al. Deletion analysis of the p16 tumor suppressor gene in gastrointestinal mucosa-associated lymphoid tissue lymphomas. Gastroenterology. 1997;112:1871-5.

    Article  PubMed  CAS  Google Scholar 

  55. Pui CH, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol. 2009;36(4 Suppl 2):S2-16.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathophysiology, School of Medicine, National University of Athens, Athens, Greece

    Michael Voulgarelis & Haralampos M. Moutsopoulos

Authors
  1. Michael Voulgarelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haralampos M. Moutsopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Voulgarelis, M., Moutsopoulos, H.M. (2011). Treatment of B-Cell Lymphoma. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_37

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_37

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation